Objectives: We aimed to identify the target antigens for combined central and peripheral demyelination (CCPD).
Multiple sclerosis (MS) affects the CNS, with no involvement of the peripheral nervous system (PNS). In contrast, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is typically restricted to the PNS and can be considered a peripheral nerve analog of MS. However, the phenotype of CIDP is wide and the disease can be associated with CNS demyelination. Patients presenting with combined central and peripheral demyelination (CCPD) have occasionally been reported using various diagnostic names including chronic demyelinating peripheral neuropathy associated with multifocal CNS demyelination, peripheral neuropathy with MS, CIDP with CNS involvement, and relapsing demyelinating disease affecting both the CNS and PNS. 1 CCPD currently has no clear clinical definition and appears to encompass heterogeneous conditions including acute, relapsing, and chronic subtypes.
This combined demyelinating condition has raised the issue of whether this is a unique condition due to a common immunopathogenic mechanism, or simple coincidence of restricted demyelinating disorders (MS and CIDP). Several clinical, laboratory, and neuroimaging features in patients with CCPD are atypical for MS, including bilateral optic neuritis, an absence of oligoclonal immunoglobulin G (IgG) bands (OCB), and gray matter involvement. [2] [3] [4] Therefore, a distinct immune-mediated mechanism causing both central and peripheral demyelination is postulated in this entity; however, no antigenic target common to the CNS and PNS has yet been identified. In this study, as one of target antigens for CCPD, we identified neurofascin, which is a member of the L1 subgroup of adhesion molecules expressed at the nodes of Ranvier and the paranodes in both the CNS and PNS, 5 and characterized the clinical profiles of anti-neurofascin antibody-positive CCPD patients. METHODS Patients. We obtained clinical data and sera from 7 patients with CCPD, 16 patients with CIDP based on the research criteria for diagnosis of CIDP, 6 20 patients with MS according to the revised McDonald criteria, 7 20 patients with Guillain-Barré syndrome (GBS) (10 with acute motor axonal neuropathy [AMAN], 8 7 with acute inflammatory demyelinating polyneuropathy [AIDP], 8 and 3 unclassified) , 21 patients with other neuropathies (ON), and 23 healthy controls (HC). Written informed consent was obtained. All patients with CCPD were confirmed to have CNS lesions suggestive of demyelination by MRI and demyelinating neuropathy by peripheral nerve conduction studies. Among them, 3 cases (patients 1, 2, and 6 in the table) were diagnosed with CCPD at Kyushu University Hospital between 2001 and 2010 and used for initial screening. The other 4 cases were consecutively referred to Kyushu University from the coauthors' institutions in 2011 for the anti-neurofascin antibody assay. All CCPD samples were subjected to immunoblotting, ELISA, and cell-based assays. Only one patient in the MS group had abnormal nerve conduction study findings due to carpal tunnel syndrome. Fourteen patients in the CIDP group showed typical symmetric distal and proximal weakness, while 2 patients had asymmetric involvement. Four patients with CIDP had abnormalities on brain MRI: 3 with small ischemic lesions and one with mild hydrocephalus. ON included inherited, vasculitic, and diabetic neuropathies. Samples were collected from patients receiving no immunologic treatments. There were no significant differences in the age and sex of each group except for patients with CCPD, who were younger than those in the other groups.
Immunofluorescence assay. The sciatic nerves of female Sprague-Dawley rats were collected and frozen immediately after dissection. Longitudinal sections of the sciatic nerves were fixed for 3 minutes in 10% formalin just before immunohistochemical staining. We performed an indirect immunofluorescence assay on these samples using sera from human subjects (diluted 1:60) followed by detection with a fluorescein-conjugated goat antibody to human IgG (Southern Biotechnology Associates, Birmingham, AL). We also undertook double immunostaining to characterize the localization of patients' IgG binding sites, using rabbit IgG antibodies specific for neurofascin, gliomedin (Abcam Plc., Cambridge, UK), or contactin-associated protein 1 (Caspr) (Millipore Corporation, Temecula, CA), together with an Alexa 594conjugated antibody to rabbit IgG as a detector reagent (Southern Biotechnology Associates). Images were captured using a fluorescence microscope (Biozero, BZ-8000; Keyence, Osaka, Japan).
Extraction of tissue proteins. Detailed methods for the extraction of tissue proteins are described in the e-Methods on the Neurology ® Web site at www.neurology.org.
Immunoblotting and immunoabsorption. Detailed methods for immunoblotting using extracted PNS and CNS proteins and recombinant rat neurofascin protein and immunoabsorption by recombinant neurofascin protein are described in the e-Methods.
Cell-based assay. We also performed a cell-based anti-neurofascin antibody detection assay using neurofascin-transfected cells. Human embryonic kidney 293 cells maintained in medium containing 10% fetal calf serum were seeded at 5,000 cells/well onto 8-well chamber slides 24 hours before transfection. Because neurofascin has 2 major forms, neurofascin 186 (NF186) and neurofascin 155 (NF155), the cells were transfected with 100 ng/well of either green fluorescent protein (GFP)-NF155 or GFP-NF186 fusion protein expression vector containing a full-length cDNA encoding human NF155 or NF186, respectively (OriGene Technologies, Inc., Rockville, MD), using FuGENE6 transfection reagent (Roche, Basel, Switzerland). After blocking with 10% goat serum, the GFP-NF155-expressing cells were incubated with human serum (1:100) or CSF samples (1:1) diluted with Dulbecco's modified Eagle medium for 1 hour at 37°C without cell fixation, washed in phosphate-buffered saline, and then visualized using an Alexa 594-conjugated goat antibody to human IgG (Invitrogen, Carlsbad, CA). The fluorescence of unfixed cells was observed using a confocal laser scanning microscope (Nikon A1). The anti-neurofascin antibody assay was performed at least twice for each sample, and those that gave a positive result twice were deemed to be positive.
ELISA. We coated polystyrene microtiter ELISA plates (ICN Biomedicals, Inc., Costa Mesa, CA) with recombinant rat neurofascin protein (0.2 mg/well). After blocking, 50 mL of serum (1:200) was applied to the wells at room temperature and plates were incubated for 1 hour. After washing, we applied a horseradish peroxidase-conjugated goat antibody to human IgG (1:1000; Southern Biotechnology Associates) and developed the plates using o-phenylenediamine dihydrochloride (Sigma, St. Louis, MO). The optical density (OD) was quantified at 450 nm using an Immunomini NJ-2300 plate reader (Inter Med, Osaka, Japan).
Statistical analysis. Data are expressed as means and SEM. We used 1-way analysis of variance for comparisons of ages, and Fisher exact probability test for comparisons of the frequencies of sex in each group. We also used 1-way analysis of variance followed by Dunnett multiple comparison tests for comparisons of the mean OD values in each group (figure 3B). Receiver operating characteristic (ROC) curves were generated and area under the curve was calculated to estimate cutoff OD values for the anti-neurofascin ELISA assay to accurately discriminate patients with CCPD. Statistical analyses were performed using JMP 9.0.2, and the threshold for significance was set at p , 0.05.
Standard protocol approvals. The research protocol for this retrospective study and the data privacy procedures for consented samples were approved by the Kyushu University ethics committee (no. 24-100).
RESULTS Screening and identification of target proteins
in patients with CCPD and CIDP. During screening by immunofluorescence assay, sera from controls showed no significant immunoreactivity toward the rat sciatic nerve ( figure 1A ). Four patients with CIDP showed diffuse binding of serum IgG to the myelin sheath (figure 1B). Two patients with CCPD (patients 1 and 2) showed a characteristic pattern of serum IgG binding to sections of sciatic nerves, with a cross-like appearance at fixed intervals (figure 1C). Dual labeling experiments for serum IgG binding and nodal or paranodal proteins revealed a partial overlay of serum IgG binding with gliomedin labeling at the node of Ranvier and with Caspr labeling at the paranode. By contrast, pan-neurofascin immunostaining showed nearly perfect colocalization with serum IgG binding at both the node and paranode (figure 1, D-L).
Immunoblotting experiments revealed that the serum IgG from CCPD patient 1 bound to both rat sciatic nerve (PNS) and spinal cord (CNS) lysates as 2 dense bands and one additional thin band between 100 and 150 kD ( figure 2A ). Serum from patient 2 also showed 2 thick bands and one thin band between 100 and 150 kD, and an additional faint band between 150 and 250 kD. The mobility of the 2 dense bands stained by the patients' sera was in accord with that stained by anti-NF155 monoclonal antibody, but not with that stained by anti-NF186 polyclonal antibody. The 2 dense bands disappeared when the patients' sera were preincubated with recombinant NF155 while the lower-molecular-weight thin band in patients 1 and 2 and the higher-molecularweight faint band in patient 2 still existed ( figure 2B ). NF155 comprises 2 isoforms, termed neurofascin 155 high and low (NF155H and NF155L, respectively), which differ in terms of their N-linked glycosylation. 9 These findings suggest that the 2 dense bands correspond to NF155H and NF155L, whereas the lowermolecular-weight band in patients 1 and 2 and the higher-molecular-weight band in patient 2 were nonspecific. The other CCPD cases showed no clear bands on immunoblotting.
Anti-neurofascin antibody in the cell-based assay and ELISA in patients with CCPD and other neurologic disorders and HC. We examined the presence/absence of IgG antibody to neurofascin in patients with CIDP, MS, AMAN, AIDP, and ON and HC using a cell-based assay and ELISA. In the cell-based assay, antibodies against NF155 were detected in sera from 5 patients with CCPD (patients 1-5 in the table), whereas all others were negative (figure 3, A-C). In patients 1 and 2, further analyses of CSF samples confirmed both to be positive for anti-NF155 antibody (figure 3, D-F). However, these patients' sera were negative for NF186 in the cell-based assay (data not shown). In the ELISA for NF155, among the 5 patients with CCPD who were positive for anti-neurofascin Pt.1 and 2 correspond to patients 1 and 2 in the table, respectively. Three bands are visible between 100 and 150 kD in patients 1 and 2. The mobility of the 2 dense bands stained by the patients' sera is in accord with that stained by anti-NF155 monoclonal antibody, but not with that stained by anti-NF186 polyclonal antibody. The bands of the recombinant NF155 protein and rat brain NF155 do not line up perfectly because recombinant NF155 is His-tagged, which causes it to have a distinct electrophoretic mobility. The NF186 band is visible only in rat CNS samples because NF186 is mainly expressed in CNS tissues. 18 (B) Immunoabsorption experiments using sera from patients 1 and 2. By preincubation of diluted patients' sera (1:100) with recombinant rat NF155 at 2 different concentrations, the 2 upper dense bands are not visible while the lower thin band in patients 1 and 2 and the higher-molecular-weight thin band between 150 and 250 kD in patient 2 still exist, suggesting that the patients' antibodies specifically bind to NF155 while the lower thin band in both patients and the higher-molecular-weight thin band in patient 2 are nonspecific. Ab 5 antibody; CCPD 5 combined central and peripheral demyelination; NF 5 neurofascin; PNS 5 peripheral nervous system. antibody in the cell-based assay, 3 showed very high serum OD values (figure 3G, patients 1-3 in the table) and 2 had medium OD values (patients 4 and 5). One patient with CCPD (patient 7) who showed a negative result on the cell-based assay had a medium OD value by ELISA. Mean OD values in patients with CCPD were significantly higher than those in other disease groups and HC ( figure 3G ). Logistic regression analysis showed that when OD values of samples from patients with CCPD were compared with samples from patients with other neurologic disorders, including MS, CIDP, GBS, and ON, and samples from HC, the area under the ROC curve was 0.95. When the cutoff point was estimated from the ROC curve, the ideal cutoff OD value was estimated as 0.435. According to the cutoff point for the OD value, the numbers of antineurofascin antibody-positive patients in each disease category were as follows: 6/7 patients with CCPD (86%); 2/20 patients with MS (10%); 4/16 patients with CIDP (25%); 2/10 patients with AMAN (20%); 1/7 patients with AIDP (14.3%); 0/21 patients with ON (0%); and 0/23 HC (0%). Sera from all CIDP, MS, AMAN, and AIDP patients who had OD values higher than the cutoff level by ELISA were found to be negative by the cell-based assay ( figure 3G, empty dots) .
Case presentations and comparison of clinical features between anti-neurofascin-positive and -negative CCPD patients. The clinical findings of the 7 patients with CCPD are summarized in the table, and each case is described in appendix e-1. The age at onset in the 5 patients with CCPD who were anti-neurofascin antibody positive by the cell-based assay ranged from 16 to 48 years, and both sexes were involved (male:female, 2:3). The CNS and PNS were involved simultaneously or with a short interval in 3, whereas 2 showed a long interval between CNS and PNS involvement. All had high CSF protein levels and one of the 5 had OCB. Multifocal white matter lesions were seen in 4, with contrast enhancement in 2, but one showed diffuse white matter lesions ( figure 4E) , which is atypical of MS. Spinal cord lesions were present in 2 of 5 on MRI. Visual evoked potentials were abnormal in 4 of 5 patients examined. Four met the McDonald criteria, while one did not. All fulfilled the established criteria for CIDP (figure 4, F and G). In the 5 anti-neurofascin antibody-positive CCPD patients, corticosteroids were only partially effective or ineffective except in one with a favorable response of the CNS lesions. IVIg administrations were effective in all 4 patients that received them, while plasma exchanges were effective in 2 of 3. These clinical features were similar to those of the 2 anti-neurofascin antibody-negative CCPD patients; however, in both anti-neurofascin antibodyseronegative CCPD patients, corticosteroids were effective for both CNS and PNS lesions.
DISCUSSION This study reveals the high frequency of anti-neurofascin antibody in patients with CCPD. We also confirmed that some patients with MS, CIDP, AMAN, and AIDP were positive for anti-neurofascin antibodies by ELISA, as reported previously. The discrepancies among the results of the ELISA, immunoblotting, and cell-based assays may be attributable to differences in epitope, i.e., linear or conformational, as well as the sensitivities and specificities of the 3 assays. Further refinement of the assay methods and a large-scale study are called for to solve this issue in the future. As CCPD is an extremely rare disease, only 3 of the patients described were our own institutional cases. Although selection bias was not completely eliminated, on referral to our clinic for anti-neurofascin antibody assay, no selection was made; therefore, we believe that the recruitment of patients with CCPD would not have severely distorted our findings. With these reservations in mind, the following are characteristic of CCPD patients with anti-neurofascin antibodies: 1) CNS and PNS involvement occur either simultaneously or sequentially with a short or long interval; 2) peripheral nerve demyelination is indistinguishable from CIDP; 3) CNS involvement is mostly typical for MS, in which spinal cord lesions and gadolinium enhancement of the lesions can develop, but occasionally atypical, demonstrating diffuse cerebral white matter lesions; 4) CSF OCB are negative in most cases while CSF protein levels show variable degrees of increase; and 5) the response to corticosteroids is limited, while IVIg and plasma exchanges are beneficial for both CNS and PNS lesions.
In a previous report, spreading of autoimmunity from central to peripheral or peripheral to central myelin was proposed in patients with either MS or CIDP. 8 However, 3 of 5 patients with CCPD who were positive for anti-neurofascin antibodies by the cell-based assay showed simultaneous or sequential occurrence of both CNS and PNS lesions within a short interval, suggesting that the anti-neurofascin antibody can emerge at the onset or very early in the course of the disease, which is contrary to the epitope spreading hypothesis. By contrast, in the other 2 anti-neurofascin antibody-positive cases with a long interval between CNS and PNS lesion development, anti-neurofascin antibody could be produced by epitope spreading. Nonetheless, such secondarily produced antibody may exert pathogenic actions extending the original lesions from the PNS to the CNS or vice versa. The presence of anti-neurofascin antibody in the CSF further supports its involvement in the formation of CNS lesions in addition to the PNS lesions. Anti-neurofascin antibody-positive CCPD patients fulfilled the European Federation of Neurological Societies/Peripheral Nerve Society diagnostic criteria for CIDP. 10 By contrast, CNS involvement was atypical in one anti-neurofascin antibody-positive patient who had a chronic course and showed diffuse white matter changes on brain MRI. Of interest is that many reported patients with CCPD, including our antibody-positive patients, were negative for OCB, which are detected in .90% of patients with MS. 11 These findings suggest that anti-neurofascin antibody-positive CCPD patients could have a somewhat distinct CNS involvement from that in typical MS patients. It is thus suggested that anti-neurofascin antibody-positive CCPD is a unique condition due to a common immunopathogenic mechanism between CNS and PNS demyelination rather than a simple coincidence of MS and CIDP. An autoantibody response to neurofascin has been reported in patients with MS, particularly in those with chronic progressive MS, and immune-mediated axonal injury and a potential contribution to axonal pathology have been proposed. 12 Autoantibody responses to neurofascin were also reported in patients with GBS and CIDP. [13] [14] [15] Among the patients with GBS and CIDP in that study, only 4% were positive for neurofascin by a cell-based assay, although CNS involvement was not thoroughly examined in the positive cases. 14 Two patients with CIDP who had high titers of antineurofascin antibody by ELISA benefited from plasma exchange. 14 Our findings are partly in accordance with the observations described in a recent report, 14 and thus suggest that a high titer of anti-neurofascin antibodies recognizing neurofascin molecules expressed on the cell membrane could also be associated with CCPD, and might be pathogenic. In this case, the CNS and PNS are possibly involved together, because neurofascin exists in both tissues. In a small fraction of AMAN, AIDP, CIDP, and MS cases with high titers of antineurofascin antibody, as reported previously, [12] [13] [14] [15] investigations for subclinical involvement of the CNS and PNS may be recommended.
Neurofascins are transmembrane adhesion molecules expressed at the nodes and paranodes of both the CNS and PNS. 5, 16, 17 The 2 major isoforms of neurofascin have different expression patterns. NF186 is an axonal membrane protein contributing to assembly of voltage-dependent sodium channels at high concentrations at the node of Ranvier. NF155 is expressed by glial cells (oligodendrocytes and Schwann cells) at the paranodes and connects the myelin sheath to the axon via binding to contactin-1 and Caspr. The autoantibodies in patients with CCPD appear to recognize mainly NF155 that is present at the paranode based on the findings of the cell-based assay and immunoabsorption experiments; however, some reactivity against the node was also observed in immunohistochemistry experiments using PNS tissue sections, suggesting additional binding to NF186 at the nodal axolemma in situ, at least in some patients. Our findings indicate that autoantibodies attacking axo-glial integrity at the paranodes and nodes, but not compacted myelin, may cause inflammatory demyelination in both the CNS and PNS. The beneficial responses to IVIg and plasma exchanges in patients with CCPD who are anti-neurofascin antibody positive also support the notion that this autoantibody may contribute to the demyelinating process. Thus, the results of our study suggest that the presence of anti-neurofascin antibodies is a potential diagnostic biomarker for patients with CCPD who could benefit from IVIg and plasma exchanges.
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